Related Experiment Video
Updated: Jun 21, 2026
09:36
Live-Cell Imaging Assays to Study Glioblastoma Brain Tumor Stem Cell Migration and Invasion
Published on: August 29, 2018
[Epigenetic analyses of brain tumor stem cells]
Atsushi Natsume1, Yutaka Kondo, Toshihiko Wakabayashi
1Department of Neurosurgery, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan.
Brain and Nerve = Shinkei Kenkyu No Shinpo
|July 22, 2009
Summary
Early epigenetic changes, including histone modifications like H3K27-3Me, are crucial in developing human brain tumors from cancer stem cells. EZH2 enzyme plays a key role, suggesting potential epigenetic therapies.
Area of Science:
- Epigenetics
- Oncology
- Neuroscience
Context:
- Cancer stem cells (CSCs) are implicated in human neoplasia.
- The early epigenetic events driving malignant precursor development are largely unknown.
- Brain tumor stem cells (BTSCs) are a focus for understanding tumor initiation.
Purpose:
- To review epigenetic modifications in human brain tumor induction.
- To highlight the role of polycomb-repressive complex-mediated histone modifications, specifically H3K27-3Me, in BTSCs.
- To discuss the involvement of EZH2 and explore epigenetic therapy prospects.
Summary:
- This review focuses on epigenetic alterations in human brain tumor development, particularly within brain tumor stem cells (BTSCs).
- Key epigenetic mechanisms examined include polycomb-repressive complex-mediated histone H3 lysine 27 tri-methylation (H3K27-3Me) and DNA methylation patterns, which silence tumor-suppressor genes.
- The role of EZH2 histone methyltransferase, a component of polycomb repressive complex 2, in brain tumor formation is discussed, alongside potential epigenetic therapeutic strategies.
Impact:
- Provides insights into the epigenetic landscape of brain tumor initiation.
- Identifies EZH2 as a potential therapeutic target in brain tumors.
- Suggests avenues for developing novel epigenetic therapies for brain malignancies.
Related Concept Videos
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...